Difference between revisions of "Part:BBa K2549005:Design"
m |
|||
(One intermediate revision by the same user not shown) | |||
Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K2549005 short</partinfo> | <partinfo>BBa_K2549005 short</partinfo> | ||
− | |||
<partinfo>BBa_K2549005 SequenceAndFeatures</partinfo> | <partinfo>BBa_K2549005 SequenceAndFeatures</partinfo> | ||
===Design Notes=== | ===Design Notes=== | ||
− | The heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) were fused together using a glycine-rich peptide linker(3 repeats of GGGGS, or G4S)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>. | + | The heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) were fused together using a glycine-rich peptide linker (3 repeats of GGGGS, or G4S)<ref>Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005</ref>. |
===Source=== | ===Source=== | ||
− | + | From IDT (gBlock), codon optimized for human | |
===References=== | ===References=== |
Latest revision as of 13:13, 12 October 2018
anti-CD19
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000INCOMPATIBLE WITH RFC[1000]Illegal BsaI site found at 444
Design Notes
The heavy-chain variable region (αCD19a) and light-chain variable region (αCD19b) were fused together using a glycine-rich peptide linker (3 repeats of GGGGS, or G4S)[1].
Source
From IDT (gBlock), codon optimized for human
References
- ↑ Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med, 2016 Mar;374(10):998 PMID: 26962747; DOI: 10.1056/NEJMx160005